NCT06487377View on ClinicalTrials.gov

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pancreatic CancerColorectal Cancer
Interventions
BIOLOGICAL

IX001 TCR-T cells

IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pudong Hospital, Shanghai

All Listed Sponsors
collaborator

ImmuXell Biotech Ltd.

UNKNOWN

lead

Shanghai Pudong Hospital

OTHER